Total Payments
$1.6M
2024 Payments
$212,775
Companies
48
Transactions
2,963
Medicare Patients
12,017
Medicare Billing
$921,549
Payment Breakdown by Category
Other$1.1M (72.7%)
Consulting$184,560 (11.8%)
Travel$168,460 (10.8%)
Food & Beverage$46,525 (3.0%)
Research$25,830 (1.7%)
Education$807.60 (0.1%)
Gifts$0.49 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 427 | 65.1% |
| Consulting Fee | $184,560 | 77 | 11.8% |
| Travel and Lodging | $168,460 | 412 | 10.8% |
| Honoraria | $85,831 | 24 | 5.5% |
| Food and Beverage | $46,525 | 1,982 | 3.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $33,300 | 11 | 2.1% |
| Unspecified | $25,830 | 2 | 1.7% |
| Education | $807.60 | 27 | 0.1% |
| Gift | $0.49 | 1 | 0.0% |
Payments by Type
General
$1.5M
2,961 transactions
Research
$25,830
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $175,114 | 310 | $0 (2024) |
| GENZYME CORPORATION | $159,852 | 202 | $0 (2024) |
| ABBVIE INC. | $147,905 | 378 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $143,839 | 231 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $137,563 | 218 | $0 (2024) |
| UCB, Inc. | $132,106 | 183 | $0 (2024) |
| Celgene Corporation | $104,535 | 136 | $0 (2019) |
| Amgen Inc. | $96,849 | 200 | $0 (2024) |
| LEO Pharma Inc. | $89,784 | 156 | $0 (2024) |
| PFIZER INC. | $73,486 | 196 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $212,775 | 404 | Regeneron Healthcare Solutions, Inc. ($41,154) |
| 2023 | $248,579 | 463 | GENZYME CORPORATION ($49,768) |
| 2022 | $218,915 | 445 | LEO Pharma Inc. ($46,717) |
| 2021 | $181,085 | 301 | GENZYME CORPORATION ($43,757) |
| 2020 | $95,588 | 211 | Novartis Pharmaceuticals Corporation ($24,870) |
| 2019 | $258,831 | 420 | Novartis Pharmaceuticals Corporation ($74,452) |
| 2018 | $126,179 | 270 | Celgene Corporation ($35,161) |
| 2017 | $219,173 | 449 | Celgene Corporation ($38,105) |
All Payment Transactions
2,963 individual payment records from CMS Open Payments — Page 3 of 119
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $27.86 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/02/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 10/30/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $8.16 | General |
| Category: Dermatology | ||||||
| 10/29/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Dermatology | ||||||
| 10/29/2024 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: Dermatology | ||||||
| 10/28/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: DERMATOLOGY | ||||||
| 10/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $18.89 | General |
| Category: Inflammation | ||||||
| 10/24/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $659.46 | General |
| Category: Immunology | ||||||
| 10/24/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $123.97 | General |
| Category: Immunology | ||||||
| 10/24/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | In-kind items and services | $40.00 | General |
| Category: Immunology | ||||||
| 10/24/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $36.98 | General |
| Category: Inflammation | ||||||
| 10/23/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $27.11 | General |
| Category: Dermatology | ||||||
| 10/23/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/23/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $4.83 | General |
| Category: Immunology | ||||||
| 10/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $10.06 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/16/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,560.00 | General |
| Category: DERMATOLOGY | ||||||
| 10/16/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Inflammation | ||||||
| 10/16/2024 | LEO Pharma Inc. | ADBRY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,900.00 | General |
| Category: DERMATOLOGY | ||||||
| 10/16/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Inflammation | ||||||
| 10/16/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: IMMUNOLOGY | ||||||
| 10/13/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Immunology | ||||||
| 10/11/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| REGISONIC BCC BCCNS DISEASE REGISTRY | Genentech, Inc. | $22,964 | 1 |
| CC-10004-PSOR-008 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis | Celgene Corporation | $2,866 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,684 | 3,899 | $634,123 | $211,299 |
| 2022 | 21 | 2,861 | 4,066 | $683,716 | $236,857 |
| 2021 | 23 | 3,235 | 4,955 | $722,488 | $263,515 |
| 2020 | 17 | 3,237 | 4,747 | $545,203 | $209,879 |
Total Patients
12,017
Total Services
17,667
Medicare Billing
$921,549
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 416 | 579 | $220,020 | $64,066 | 29.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 490 | 572 | $85,800 | $33,109 | 38.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 519 | 844 | $84,400 | $30,415 | 36.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 369 | 371 | $111,300 | $26,011 | 23.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 216 | 228 | $25,438 | $15,955 | 62.7% |
| 11106 | Incision biopsy, first skin growth | Office | 2023 | 97 | 98 | $19,600 | $10,734 | 54.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 159 | 167 | $20,875 | $7,439 | 35.6% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 103 | 159 | $12,480 | $5,742 | 46.0% |
| 11107 | Incision biopsy, each additional skin growth | Office | 2023 | 56 | 92 | $7,360 | $4,755 | 64.6% |
| 12032 | Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | Office | 2023 | 19 | 20 | $6,000 | $4,180 | 69.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 131 | 593 | $17,430 | $2,539 | 14.6% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 14 | 15 | $6,975 | $2,165 | 31.0% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 11 | 14 | $3,640 | $1,662 | 45.7% |
| 11901 | Injection into skin growth, more than 7 growths | Office | 2023 | 17 | 32 | $5,280 | $1,416 | 26.8% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 19 | 19 | $4,750 | $831.06 | 17.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 23 | $1,725 | $227.04 | 13.2% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 30 | 73 | $1,050 | $53.98 | 5.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 415 | 589 | $223,820 | $65,888 | 29.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 685 | 899 | $134,850 | $52,985 | 39.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 350 | 353 | $105,900 | $24,639 | 23.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 407 | 637 | $63,700 | $23,828 | 37.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 229 | 252 | $28,116 | $17,689 | 62.9% |
| 11106 | Incision biopsy, first skin growth | Office | 2022 | 91 | 92 | $16,280 | $10,245 | 62.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 158 | 168 | $21,000 | $7,302 | 34.8% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 108 | 159 | $12,560 | $5,794 | 46.1% |
About Dr. Melissa Knuckles, M.D
Dr. Melissa Knuckles, M.D is a Dermatology healthcare provider based in Corbin, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1821074360.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Melissa Knuckles, M.D has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $212,775 received in 2024. These payments were reported across 2,963 transactions from 48 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.0M).
As a Medicare-enrolled provider, Knuckles has provided services to 12,017 Medicare beneficiaries, totaling 17,667 services with total Medicare billing of $921,549. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Corbin, KY
- Active Since 12/16/2005
- Last Updated 05/05/2020
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821074360
Products in Payments
- DUPIXENT (Biological) $236,138
- Otezla (Drug) $164,264
- COSENTYX (Biological) $135,867
- ADBRY (Biological) $86,687
- Cimzia (Drug) $77,638
- ILUMYA (Biological) $77,444
- SKYRIZI (Biological) $61,743
- EUCRISA (Drug) $46,551
- Sotyktu (Drug) $44,618
- SILIQ (Drug) $42,861
- RINVOQ (Biological) $39,866
- DUPIXENT DUPILUMAB INJECTION (Biological) $37,644
- AKLIEF (Drug) $37,580
- DUPIXENT (Drug) $34,767
- Bimzelx (Biological) $31,799
- Winlevi (Drug) $29,625
- TALTZ (Drug) $27,120
- VTAMA (Drug) $26,867
- CIBINQO (Drug) $25,262
- Ilumya (Biological) $25,104
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.